Use of 10-valent pneumococcal conjugate vaccine in Kenya has led to substantial reductions in vaccine-type pneumococcal carriage and invasive pneumococcal disease. However, analysis of recent surveillance data indicates an outbreak of vaccine-type serotype 1 in 2023 in Kibera, Kenya. Continued monitoring of invasive pneumococcal disease in Kenya is warranted.
Keywords: 10-valent pneumococcal vaccine; Kenya; Kibera; Nairobi; Streptococci; Streptococcus pneumoniae; bacteria; outbreak; pneumococcal diseases; respiratory infections; vaccines.